A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors

Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial

(2017) Robert L Coleman et al.   LANCET ONCOLOGY

A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors

(2015) E. G. Chiorean et al.   CLINICAL CANCER RESEARCH

A Phase I Dose Escalation and Expansion Study of the Anticancer Stem Cell Agent Demcizumab (Anti-DLL4) in Patients with Previously Treated Solid Tumors

(2014) D. C. Smith et al.   CLINICAL CANCER RESEARCH

Anti-DLL4 Has Broad Spectrum Activity in Pancreatic Cancer Dependent on Targeting DLL4-Notch Signaling in Both Tumor and Vasculature Cells

(2012) W.-C. Yen et al.   CLINICAL CANCER RESEARCH

The Mutational Landscape of Head and Neck Squamous Cell Carcinoma

(2011) N. Stransky et al.   SCIENCE

Anti-DLL4 Inhibits Growth and Reduces Tumor-Initiating Cell Frequency in Colorectal Tumors with Oncogenic KRAS Mutations

(2010) M. Fischer et al.   CANCER RESEARCH

DLL4 Blockade Inhibits Tumor Growth and Reduces Tumor-Initiating Cell Frequency

(2009) Timothy Hoey et al.   Cell Stem Cell

PI3K pathway alterations in cancer: variations on a theme

(2008) T L Yuan et al.   ONCOGENE